| scholarly article | Q13442814 |
| P50 | author | Spyros Retsas | Q47364959 |
| P2860 | cites work | Treating Cancer by Targeting the Immune System | Q56899478 |
| A multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III) | Q71186808 | ||
| Taxol and vinorelbine: a new active combination for disseminated malignant melanoma | Q71347101 | ||
| Clinical and histologic involvement of regional lymph nodes in malignant melanoma. Adjuvant vindesine improves survival | Q72359934 | ||
| Identification of a new HLA-A(*)0201-restricted T-cell epitope from the tyrosinase-related protein 2 (TRP2) melanoma antigen | Q74009023 | ||
| Prognostic factors of cutaneous melanoma and a new staging system proposed by the American Joint Committee on Cancer (AJCC): validation in a cohort of 1284 patients | Q77712131 | ||
| Systemic treatment of melanoma: quo vadis oncologist? | Q80163026 | ||
| Bad seeds, bad science, and fairly black cats? | Q82074070 | ||
| Randomized phase II trials: inevitable or inadvisable? | Q84081818 | ||
| Inhibition of Mutated, Activated BRAF in Metastatic Melanoma | Q27860458 | ||
| Improved Survival with Ipilimumab in Patients with Metastatic Melanoma | Q27861062 | ||
| Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma | Q33384029 | ||
| Resistance to BRAF inhibition in melanomas | Q34166376 | ||
| Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma | Q34563261 | ||
| Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis | Q36612290 | ||
| Reflecting on the 2001 American Joint Committee on Cancer Staging System for melanoma. | Q37033461 | ||
| Prognostic factors in 1,521 melanoma patients with distant metastases | Q40479959 | ||
| Central nervous system involvement in malignant melanoma. | Q44782677 | ||
| Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group | Q46619788 | ||
| Randomized Phase II Trials: Misleading and Unreliable | Q53074049 | ||
| Treatment at random: the ultimate science or the betrayal of Hippocrates? | Q53315218 | ||
| Melanoma--an unlikely poster child for personalized cancer therapy. | Q54651545 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 269-272 | |
| P577 | publication date | 2011-06-01 | |
| P1433 | published in | Journal of the Royal Society of Medicine | Q6296198 |
| P1476 | title | Latest developments in the treatment of melanoma: 'a penicillin moment for cancer'? | |
| P478 | volume | 104 |
| Q37031656 | Emerging options for the treatment of melanoma - focus on ipilimumab |
| Q54484191 | Hepatocyte growth factor in the neighborhood reverses resistance to BRAF inhibitor in melanoma. |
| Q36292634 | Ipilimumab (yervoy) prolongs survival in advanced melanoma: serious side effects and a hefty price tag may limit its use. |
| Q39406388 | Specifically targeting ERK1 or ERK2 kills melanoma cells |
Search more.